EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor

Cameron Lanier iD, Tyler Melton, Kelly Covert

Annals of Pharmacotherapy · 2025-06 · 59 (6) · 570-576

DOI: 10.1177/10600280241279904 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 27.09.2024. Verfasst von Cameron Lanier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johnson City Medical Center, Ballad Health, Johnson City, TN, USA. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Cefepime, Anti-Bacterial Agents, Urinary Tract Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT). Data Sources: A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May 2024). Search terms included: “cefepime-enmetazobactam” or “cefepime” or “enmetazobactam” or “cefepime” or “novel beta-lactamase inhibitor” and “complicated urinary tract infection” or “cUTI.” Conference abstracts, bibliographies, clinical trials, and drug monographs were included for review. Study Selection and Data Extraction: Relevant studies in English and clinical trials conducted in humans were reviewed. Data Synthesis: In February 2024, the Food and Drug Administration (FDA) approved the combination beta-lactam/beta-lactamase inhibitor (BL/BLI) FEP-EMT for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis following the completion of the Phase III ALLIUM trial comparing it to piperacillin-tazobactam (TZP). The trial resulted in 79.1% of the FEP-EMT group versus 58.9% of the TZP group meeting the primary outcome of clinical cure and microbiological eradication (95% CI 21.2 [14.3 to 27.9]). Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents: This review describes the use of FEP-EMT for the treatment of cUTI and compares its use to other novel BL/BLI combinations including utility in drug-resistant infections.

Conclusions

FEP-EMT provides an antimicrobial option to reduce overuse of carbapenems for extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. However, unlike other novel BL/BLI combinations, its limited spectrum of antibacterial effect for more difficult-to-treat pathogens and cost may also impact its overall utilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsCefepimeAnti-Bacterial AgentsUrinary Tract InfectionsHumansDrug CombinationsPyelonephritis

Stichwörter der Autor:innen

beta-lactambeta-lactamase inhibitorcefepime-enmetazobactamcomplicated urinary tract infectionnovel antibiotics

Substanzen

beta-Lactamase InhibitorsCefepimeAnti-Bacterial AgentsDrug Combinations

Autor:innen und Institutionen

  • Johnson City Medical Center, Ballad Health, Johnson City, TN, USA.
  • College of Pharmacy, The University of Tennessee Health Science Center, Knoxville, TN, USA.
  • Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA.

ORCID-Profile: Cameron Lanier

Zitieren

APA

Lanier, C., Melton, T., & Covert, K. (2025). Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor. Annals of Pharmacotherapy, 59(6), 570-576. https://doi.org/10.1177/10600280241279904

Vancouver

Lanier C, Melton T, Covert K. Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor. Annals of Pharmacotherapy. 2025;59(6):570-576. doi:10.1177/10600280241279904

BibTeX
@article{Lanier2025,
  author = {Lanier, Cameron and Melton, Tyler and Covert, Kelly},
  title = {Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  volume = {59},
  number = {6},
  pages = {570--576},
  doi = {10.1177/10600280241279904}
}
Kostenlos starten →